TELA logo

TELA BIO INC

TELANASDAQ
🏆 #4338 by market capEarnings Nov 11US Equity
——
Quote unavailable
🔔
Track TELA
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$44M
Small Cap
📈Revenue Growth (YoY)
15.8%
Healthy
📊Gross Margin
67.8%
High
💵FCF Margin
-39.6%
Thin
⚖️P/S Ratio
0.5x
Cheap
Otter Score
—
Insufficient data
No chart data available for TELA.

Trading Snapshot

Day Range
—
52-Week Range
$0.50 – $1.50
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
45.1M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
$80M
Last Q Revenue
$19M
P/E Ratio
-1.3
P/S Ratio
0.5x
EPS (TTM)
$-0.72
Dividend Yield
0.00%
Dilution (1yr)
+29.0%
TELA logo

TELA BIO INC

TELA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$80M▲ +15.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
67.7%▲ +0.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$34M▼ −1.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$29M▼ −32.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
51.7M▲ +29.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$5M▼ −$14M YoY
StockOtter · stockotter.space

About TELA BIO INC

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.